Skip to main content
. Author manuscript; available in PMC: 2014 Apr 1.
Published in final edited form as: Mol Cancer Ther. 2013 Jan 31;12(4):416–426. doi: 10.1158/1535-7163.MCT-12-0731

Figure 5.

Figure 5

SD1-hFc caused CDC and ADCC against mesothelin-expressing cancer cells. (A, B) CDC. A431/H9 (A) and NCI-H226 (B) cells were incubated with increasing concentrations of SD1-hFc in the presence of normal human serum (NHS, 20% vol/vol) as a source of complement The complement C1q bound H9 (C) and NCI-H226 (D) cells in the presence of SD1-hFc, not HN1 or a control hFc fusion protein. (E, F, G, H) ADCC. Freshly isolated PBMC were incubated with target cells A431/H9 (E) and NCI-H226 (F) cells at ratio of 50:1, in the presence of SD1-hFc with increasing concentrations. (G, H) Purified human NK cells incubated with target cells A431/H9 (G) or NCI-H226 (H) cells at different E:T ratios with 50 μg/ml of SD1-hFc. CDC and ADCC activity were determined by LDH assay (*: p < 0.05).